As previously reported by MAP, one of the consequences of Brexit uncertainty so far has been a drop in the number of clinical trials being carried out in the UK.
A new analysis by Fitch, reported by Reuters, has shown just how damaging the uncertainty has been to the sector so far. 597 trials were initiated in the UK in 2017, approximately a 25% drop from the yearly average of years 2009-2016.
“We know from our members that Brexit-related uncertainty is a major concern when it comes to decisions about whether to set up trials in the NHS,” said Sheuli Porkess, deputy chief scientific officer at the Association of the British Pharmaceutical Industry.
“This is why it’s vital that we get a Brexit deal to keep the investment and skills in clinical trials here in the UK.”
At present it is not known if data gathered in UK-based trials will be eligible for marketing authorisation applications to the European Medicines Agency after Brexit.